C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000062032.htmlThe evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
External timestamp
The evidence pack includes the third-party timestamp files.
C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
Open the archived HTML with saved-time metadata attached.
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
This page announces a safety alert for the hepatitis C treatment drug "Sobriard Capsule 100mg" issued by the Japanese Ministry of Health, Labour and Welfare on October 24, 2014. Three domestic deaths related to hyperbilemis that cannot exclude causality with the drug have been reported. The product label was revised with updated precautions, and healthcare providers were notified via a safety letter. Key points include regular monitoring of blood bilirubin levels during treatment, discontinuation if abnormal elevation occurs, continued monitoring after discontinuation, and patient education about warning symptoms requiring immediate medical consultation.
